Results
Besides large international variation in the likelihood to receive PD, we found that elderly patients and patients with PVD, CD, malignancy, and multiple comorbidities were significantly less likely to receive PD than HD. Overall patients starting on PD had survival benefits (HRadj 0 
Conclusions
In general, modality choice was consistent with expected survival. However, elderly patients, non-diabetic patients and those with malignancy were less likely to receive PD, while they had increased mortality risk on PD. Also a survival benefit on PD was found for male patients without comorbidity, whereas they were as likely to receive HD or PD.
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INTRODUCTION
During the last decades, the mean age of patients starting renal replacement therapy (RRT) has increased substantially, [1] [2] [3] as has the proportion of those suffering from diabetes, cardioor cerebrovascular disease, or malignancies.
Whether an end-stage renal disease (ESRD) patient will be treated with either haemodialysis (HD) or peritoneal dialysis (PD) at the start of RRT depends on practice patterns that may vary between and within countries due to several factors. Socio-economic factors, reimbursement for and (lack of) access to a particular treatment, time of referral, as well as patient or physician preferences, and patient characteristics such as age, gender, and primary renal disease all influence modality choice. [4] [5] [6] [7] [8] [9] In addition, the presence of comorbidities was demonstrated to play an important role in the choice for a particular type of dialysis. [10] [11] [12] Which type of dialysis is considered to be optimal for various patient subgroups remains controversial. An American study evaluated determinants of modality selection and demonstrated that the 'chance' of receiving PD was lower for patients with advancing age, but showed no influence of malignancies on modality selection. 12 In contrast, Couchoud et al. demonstrated that in France, PD was more likely to be chosen in elderly patients, but less frequently for patients with malignancies. 13 Many of the previous studies on dialysis modality choice were based on data from just one country, in most cases the United States, where the proportions of patients on PD and HD, and patient profiles are different from those of other countries. 12, [14] [15] [16] [17] [18] [19] Consequently, results of these studies may not be generalizable to non-American populations. In addition, most of these previous studies only adjusted for demographic and comorbid factors in their analyses, while we aim to assess modality choice within subgroups of patients based on age, gender, and the presence of diabetes, cerebro-or cardiovascular disease, or malignancy. With this large European registry-based study we subsequently aim to evaluate associations between modality choice and patient survival within these subgroups and to link these findings.
METHODS
Study population
The ERA-EDTA Registry collects a core dataset on RRT patients via national and/or regional renal registries in Europe. This dataset includes date of birth, gender, primary renal disease, date of first RRT, history of RRT (including dates and changes of modality), and date and cause of death. Only registries that provided us with additional comorbidity data at the start of dialysis were included in this study, i.e. Austria, Belgium (French-speaking part), Catalonia (Spain), Greece, Norway, Sweden, and the UK. Comorbidity data were collected as part of the routine data collection (Sweden) or within the framework of previous studies (Austria, Belgium, Catalonia, Greece, Norway, UK).
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We included patients of 20 years and older who started dialysis between 1998 and 2006. Day 91 on dialysis was considered as start of treatment, because at that moment the type of dialysis can be considered as the modality of choice. The comorbidities we studied were diabetes (DM), ischaemic heart disease (IHD), peripheral vascular disease (PVD), cerebrovascular disease (CD), and malignancies. Their classification was presented elsewhere. 20 The category DM included both DM as primary renal disease and as comorbidity in addition to another primary renal disease. The comorbidities were coded as being present or absent in the medical history at dialysis initiation. Patients were excluded if data on all 5 types of comorbidity were missing. However, in the Norwegian data of these years, no distinction was made between 'missing comorbidity' and 'no comorbidity'; in this case we assumed patients had no comorbidity.
Data analyses
To test whether our study population was representative for the total dialysis population of the participating countries, we compared patient characteristics and 3-year survival of our study population with the results for patients that were excluded due to missing data on comorbidity.
We performed logistic regression analyses to study the likelihood of receiving PD rather than HD. Patients were categorized based on age (i.e. 20-44, 45-59, 60-69, or 70 years) and on comorbidity count (i.e. none, one, two, or three to five comorbidities) to assess whether age and the number of comorbidities influenced the likelihood of receiving PD. Subsequently, we constructed separate multivariate logistic regression models to assess associations between comorbid and demographic factors and dialysis modality choice. These models included those variables that satisfied the criteria for confounding and are presented in the legends of Table 2 . 22 Results from logistic regression analyses are reported as adjusted Odds Ratios (ORadj) with 95% confidence interval (CI) for the likelihood of receiving PD rather than HD in the total dialysis population.
To assess patient survival (from day 91) on PD when compared to HD we performed Kaplan-Meier and Cox proportional-hazard analyses for several subgroups. We restricted our survival analysis to a 3-year survival, because otherwise the number of patients at risk during follow-up became too small, i.e. below 10-20% of the total study population.(23) The subgroups were defined by comorbidity count, DM, IHD, PVD, CD, and malignancy. Followup time was censored at recovery of renal function, kidney transplantation, loss of follow-up, and at the end of the observation period (December 31, 2006). Adjusted Hazard Ratios (HRs) with 95% CI for mortality were calculated using confounding variables which were the same as those in the logistic regression models as presented in the legends of Figure 2 . Cells in the survival tables were left empty when less than 30 events occurred. As previous studies on survival in dialysis patients showed different results for males and females, diabetics and non-diabetics, and different age categories, 24 we tested whether there was interaction between the variables sex, age and the separate comorbidities in our models. In the overall logistic regression analysis we found interaction between age and sex. In addition, interactions were found between DM and age and between DM and sex. Therefore we stratified our full model, and the model used to assess the association between DM and modality choice both for age and sex. In the survival analyses, interaction existed between dialysis modality and sex for patients with PVD or IHD, so stratification for sex was applied in these subgroups. The survival analysis for patients with DM was also stratified for sex based on literature.
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For subgroups the analysis was repeated using propensity scores instead of separate covariates as the application of propensity scores requires less degrees of freedom and thereby increases the power of the model. 25 Propensity scores represent either the probability of receiving PD (logistic regression analyses) or of patient survival (Cox regression analyses) for each individual patient based on all confounders in the model. All 5 analyses were based on the intention-to-treat principle and were performed using SAS 9.1 (SAS Institute Inc., Cary, NC, USA 1999-2001). 
RESULTS
Baseline characteristics
Data on comorbidity were available from 15,828 out of 23,101 (69%) patients who started dialysis between 1998 and 2006. Baseline characteristics of the included patients for the total population and for HD and PD patients separately are presented in Table 1 . In general, PD patients were younger and had less comorbid conditions as compared to HD patients. When comparing baseline characteristics between included and excluded patients (those without data on co-morbidity) their age (63 vs 62 years) and gender (62% males in both groups) were similar, but the proportion of patients on PD was lower in the study population (20% vs 28%). However, country, age and sex adjusted 3-year survival of PD patients versus HD patients was similar in both groups, i.e. HRsadj of 0.82 (95% CI: 0.75 to 0.89) for the included versus 0.81 (95% CI: 0.72 to 0.91) for the excluded patients.
Dialysis modality choice
We calculated ORsadj for the likelihood to receive PD as compared to HD treatment for several potential risk factors ( Table 2 ). The data showed a strong negative association between age and the choice for PD. Patients with IHD were as likely to receive PD as HD. Furthermore, patients with PVD, CD, or malignancy were significantly less likely to receive PD than patients without these conditions. Table 2 also illustrates differences in PD treatment between the participating countries. Except for patients in Sweden, patients in the other countries were less likely to receive PD as compared to the UK (reference group). Further analysis by country suggested similar associations between risk factors and modality choice as those presented in Table 2 with two exceptions: Catalonia (Spain) where the presence of multiple comorbidities relatively strongly increased the likelihood of receiving PD and Greece where the likelihood of receiving PD increased with age.
Patient survival
Mean follow-up time was 1.6 years, with a maximum of 3 years. In this period, 6110 patients (38.6%) died, 6641 patients (42.0%) were alive and on dialysis at the end of the observation period, 1.6% was lost to follow-up, and 17.9% received a kidney transplant (17.7% of the HD patients and 17.9% of the PD patients). During the study, 8% of the patients switched from dialysis modality, i.e. 25% of the PD patients switched to HD and 4% of the HD patients switched to PD. Switches from PD to HD occurred more often with higher age and in the presence of comorbidity. Crude survival curves for male and female patients treated with HD or PD are presented in Figure 1 . Using Cox regression models we calculated crude and adjusted HRs for the 3-year survival for PD compared to HD patients (Figure 2 ). Overall we found that initiating dialysis on PD resulted in a survival benefit with a HRadj of 0.82 (95% CI: 0.75 to 0.90). When examining patients without comorbidity, the risk of death on PD versus HD was even lower (HRadj 0.65; 95% CI: 0.53 to 0.80), but with increasing number of comorbidities the survival benefit disappeared. When studying patient survival by presence or absence of comorbidities, those patients without a specific comorbidity and patients with a malignancy had survival benefits starting on PD as compared to HD. Patients with DM, IHD, PVD, or CD had no statistically significant survival benefits on PD as compared to HD. In patients with IHD and PVD we observed interaction between dialysis modality and sex. Moreover, interactions of DM with age and sex were described in the literature. We performed stratified survival analyses in these groups accordingly (Figure 3 ). After stratification for sex, the survival advantages of PD remained in males but not in females in the presence of comorbidities. For patients with three to five comorbidities we found a HRadj of 0.81 (95% 0.62 to 1.06) for males, whereas for females the HRadj was 1.53 (95% CI 1.06 to 2.22). After additional stratification for age we found that females in the highest age category ( 70 years) already had an increased HRadj when at least one comorbidity was present (HRadj 1.28 (1.00 to 1.62; p=0.046). In patients with PVD, females tended to have worse survival outcomes on PD, whereas males tended to have better survival on PD with HRsadj of 1.27 (95% CI: 0.94 to 1.72; p=0.12) and 0.81 (95% CI: 0.64 to 1.02; p=0.08), respectively. Similar results were found for patients with IHD and DM. After additional stratification for age, the data showed that the increased risk of death in diabetic females on PD was only present in patients over 70 years of age (HRadj: 1.55; 95% CI: 1.15 to 2.08). For male patients with DM on PD, such age trend in risk of death was not found. Propensity score adjustment provided similar results. 
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Figure 2: Adjusted hazard ratios for the three year survival for PD versus HD patients (reference
Linking initial dialysis modality choice to patient survival
Finally, we linked initial dialysis modality choice to related patient survival. For this purpose, we calculated the ORsadj for modality choice within each subgroup where the patient survival on PD and HD was statistically significantly different, as depicted in Figure 2 . In most cases the ORadj for initial modality choice was in line with patient survival, i.e. if there was a survival advantage on PD, patients were more likely to receive PD as initial dialysis modality and vice versa (data not shown). However, there were some discrepancies in that particular patient groups had survival benefits on PD, whereas they were less likely to receive PD. 
DISCUSSION
The first aim of this study was to identify potential risk factors that influence modality choice in the dialysis population. We found that increasing age was associated with lower likelihood to receive PD, especially in female patients. In addition, we found that patients with PVD, CD, malignancies, or multiple comorbidities were less likely to receive PD than HD. However, the presence of DM was especially in males associated with a higher likelihood of receiving PD. There was no significant difference in receiving either PD or HD in patients with IHD and in male patients without any comorbidity. In contrast to United States data, the association between types of comorbidity and dialysis modality choice in Europe has been assessed in only few studies. Couchoud et al. studied the variability in case mix and PD selection in several French districts. In their study population of patients above 75 years of age they demonstrated that receiving treatment with PD was associated with older age, congestive heart failure, and severe behavioral disorders, but not with any type of vascular disease (of the heart, brain, or peripheral vessels). Patients with malignancy or DM less often received PD than HD as initial treatment, 13, 15 while in our study we demonstrated that older age and the presence of PVD and CD were negatively associated with the likelihood of receiving PD. This is in line with our findings suggesting different modality choice policies between countries, which, as outlined in the introduction, may be due to a variety of reasons. The presence of IHD did not affect treatment modality choice, which may be explained by the fact that IHD can be a contraindication for both dialysis modalities. In such cases nephrologists may need to choose the lesser of two evils. 10, 11 In addition, nephrologists might be more interested in the presence of congestive heart failure, but unfortunately such data were unavailable in this study. When deciding between PD and HD, nephrologists may take potential treatment effects into account as well. PD may result in a more atherogenic profile, which may accelerate preexisting coronary artery disease or contribute to atherosclerotic cardiovascular comorbidity and mortality. 26 This might explain why patients with PVD or CD at the start of RRT were less likely to receive PD. However, the differential effects of PD and HD on arterial stiffness, vascular function, oxidative stress and inflammation, and myocardial structure and function need to be evaluated more extensively. 27 For diabetic patients both modalities may have drawbacks. Diabetic patients often suffer from calcific atherosclerosis which may lead to inadequate arterial inflow and problems with the vascular access during HD treatment. 28, 29 On the other hand, the glucose load during PD treatment could worsen the metabolic status and contribute to an increased risk of atherosclerotic complications. 30 In addition, it is suggested that diabetic patients have a high peritoneal transport rate, which is associated with loss of ultrafiltration, 28, 31 and an increased risk of morbidity, technique failure, and death. 31, 32 However, the impact of high peritoneal transport rates on mortality remains controversial.
The second aim of this study was to assess patient survival in subgroups of patients. Overall we found survival benefits for patients starting on PD, but effects of dialysis modality on survival were different for males and females in different comorbidity categories. Male patients showed better survival rates on PD, even in the presence of comorbidity. In contrast, survival benefits in females were only found for those with no or few comorbidity: female patients with three to five comorbidities as well as females in the highest age category with at least one comorbidity showed increased risks of death when starting on PD. However, this latter finding is most likely due to the effect in elderly diabetic females for whom we found a 55% higher risk of death when starting on PD as compared to HD. Some previous studies comparing survival between HD and PD patients suggested that patient survival is similar for patients on HD and PD, 17, 24, [33] [34] [35] while others argued that one modality provides better results than the other. 19, [36] [37] [38] [39] [40] In agreement with our results,
McDonald et al. suggested that age and the presence of comorbidities per se are important factors influencing the association between treatment modality and survival. 17 In this study we were able to show that this is indeed the case for specific comorbidities. In a study among prevalent patients in the 1990's, Bloembergen et al. found higher mortality risks associated with PD in patients older than 55 years of age. Increased mortality risks were present in both diabetic and non-diabetic patients and in both males and females, although they turned out to be more pronounced in diabetics and females. 24 Our European study in incident patients now only shows an excess mortality risk in diabetic females over 70 years of age. When studying modality choice in relation to survival we may conclude that in most subgroups the likelihood to receive PD was in line with expected survival, or in other words, patients who were most likely to receive PD treatment, had the best expected survival if treated with that modality. However, there were a few discrepancies. First, elderly patients (age 70 years), non-diabetic patients, and those with malignancy were less likely to receive PD, although we found survival benefits on PD for these three groups. In addition, in healthy patients, i.e those without any comorbidity we found survival benefits on PD for both males and females. However, results from our logistic regression analysis showed that females were indeed more likely to receive PD, but males were as likely to receive either HD or PD. These discrepancies may be due to different factors. Nephrologists may let other medical factors prevail above increased mortality risk, they may have needed to choose for PD (e.g. because the patient's heart condition was too poor to tolerate HD) or they may have been unaware of the expected patient survival on PD in these specific subgroups. In addition, modality choice may be based on practical and social considerations. For example, elderly or poorly patients will often choose HD because they regularly have difficulties to cope with or to perform home-based therapies. Nevertheless, these contrasting results emphasize the need for more extensive research on dialysis modality choice and outcome within these specific subgroups of patients. A major strength of this study is that it is based on a large population of incident dialysis patients from well-established national and regional renal registries with high data quality. With this study we were able to compare modality choice and related patient survival within several subgroups in a number of European countries. However, also some limitations can be noted. As one study has shown, the comparison of outcomes by randomizing patients for HD or PD is not feasible. 41 A randomized trial however, is the only study design to avoid confounding by indication, which occurs when physicians select patients for one type of modality for a specific reason. In this study we lacked information on other potentially important comorbidities like congestive heart failure and on clinical parameters like residual renal function, laboratory values, and medication, which made adjustment for these factors impossible. Finally, in the survival analyses we censored patients who received a kidney transplant. As we can assume that these patients were the healthiest patients with high survival rates, censoring them might have resulted in an underestimation of the patient survival. Our study focused on survival within the first 3 years on RRT. This may have biased the results in favor of PD since previous studies demonstrated survival benefits to be dependent on time on RRT. 17, 42 In conclusion, based on data from seven European renal registries we demonstrated that patients with older age, comorbidities such as PVD, CD, and malignancy, multiple comorbidities, and those living in particular countries are less likely to receive PD as dialysis treatment. Survival benefits on PD were shown for all patients without specific comorbidities. In male patients, survival advantages were independent of the presence of comorbidity, whereas female patients on PD are suggested to have increased risks of death in the presence of comorbidity, especially the elderly females with DM. Overall we can conclude that modality choice was consistent with shown survival benefits. However, for patients of 70 years and above, non-diabetic patients, and those with malignancy, treatment modality choice did not match the expected survival, as these patients were less likely to receive PD while they showed a better survival on PD. Also for male patients without comorbidity results were not in line with each other; these patients were as likely to receive HD and PD whereas a survival advantage on PD was found. Further investigation is required to identify explanations why these specific patient groups are not more likely to receive PD and whether the overall survival would improve if more of these patients would be treated with PD. 
